Core Viewpoint - The company announced that its controlling shareholder, Everbright Industry and its subsidiaries, are planning a share transfer, which may lead to a change in the actual controller of the company [1] Group 1 - As of the announcement date, the relevant parties have not signed a formal agreement [1] - The company's stock will continue to be suspended from trading starting January 30, 2026, with an expected suspension period not exceeding three trading days [1] - During the suspension period, the company will fulfill its information disclosure obligations based on the progress of the matter [1] Group 2 - Once the matter is determined, the company will promptly issue an announcement and apply for resumption of trading [1] - Investors are advised to pay attention to investment risks, with all information subject to the company's designated information disclosure media [1]

证券代码：002462 证券简称：嘉事堂 公告编号： 2026-03 嘉事堂药业股份有限公司 关于筹划控制权变更事项进展暨继续停牌的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证信息披露的内容真实、准确、 完整，没有虚假记载、误导性陈述或重大遗漏。 一、停牌情况概述： 截至本公告披露日，相关各方正在积极推进本次交易的各项工作，交易各 方尚未签署正式协议，公司预计无法在 2026 年 1 月 30 日（星期五）上午开市 起复牌。 鉴于本次交易事项目前尚存在不确定性，为保证公平信息披露、维护公司 全体股东利益，根据《深圳证券交易所股票上市规则》《深圳证券交易所上市公 司自律监管指引第 6 号——停复牌》等相关规定，经公司向深圳证券交易所申 请，公司股票（股票代码：002462，股票简称：嘉事堂）自 2026 年 1 月 30 日 （星期五）开市起继续停牌，预计停牌时间不超过 3 个交易日。 股票停牌期间，公司将根据上述事项进展情况，严格按照有关法律法规的 规定和要求履行信息披露义务。待上述事项确定后，公司将及时发布相关公告 并申请 ...

Group 1 - The company, Jia Shi Tang (002462), has reported that as of January 20, 2026, it has over 29,000 shareholders [1]

Core Viewpoint - The announcement indicates that Jiashitang is undergoing a potential change in its controlling shareholder and actual controller due to a planned equity transfer by its shareholder, Everbright Industrial [1] Group 1: Company Announcement - Jiashitang received a written notice from its shareholder, Everbright Industrial, regarding the planning of an equity transfer [1] - The equity transfer may lead to a change in the company's controlling shareholder and actual controller [1] - Jiashitang has applied for a trading suspension from the Shenzhen Stock Exchange, effective from January 28, with an expected suspension period of no more than two trading days [1]

Company News - Ningbo Fubang expects a net profit attributable to shareholders of 50 million to 70 million yuan in 2025, representing a year-on-year growth of 3099.59% to 4379.43%. The increase is driven by a focus on core business and rising silver prices, leading to improved revenue and profitability [5][6]. - Huatu Shanding anticipates a net profit attributable to shareholders of 280 million to 420 million yuan in 2025, reflecting a year-on-year increase of 428.38% to 692.57% [5]. - Zhenlei Technology forecasts a net profit attributable to shareholders of 123 million to 145 million yuan in 2025, indicating a year-on-year growth of 529.64% to 642.26% [5]. - Shijia Photon expects a net profit of approximately 342 million yuan in 2025, representing a year-on-year increase of around 425.95% [6]. - Nanya New Materials projects a net profit attributable to shareholders of 220 million to 260 million yuan in 2025, with a year-on-year growth of 337.20% to 416.69% [6]. - Yihua Co. anticipates a net profit of 310 million to 390 million yuan in 2025, reflecting a year-on-year increase of 149.66% to 214.09% [6]. - Jiayuan Group expects a net profit attributable to shareholders of 600 million to 680 million yuan in 2025, indicating a year-on-year growth of 133.36% to 164.47% [6]. - Guotai Haitong forecasts a net profit attributable to shareholders of 27.533 billion to 28.006 billion yuan in 2025, representing a year-on-year increase of 111% to 115% [6]. - Shenwan Hongyuan anticipates a net profit attributable to shareholders of 9.1 billion to 10.1 billion yuan in 2025, reflecting a year-on-year growth of 74.64% to 93.83% [6]. - Muxi Co. expects a revenue of 1.6 billion to 1.7 billion yuan in 2025, with a year-on-year increase of 115.32% to 128.78%, but anticipates a net loss of 650 million to 798 million yuan, narrowing losses by 43.36% to 53.86% compared to the previous year [6]. Market Developments - Jia Shitang announced that its shareholder, China Everbright Industrial Group, is planning a change in company control, leading to a suspension of trading starting January 28, with an expected duration of no more than two trading days [7]. - Vanke A announced that its largest shareholder, Shenzhen Metro Group, will provide a loan of up to 2.36 billion yuan to repay bond principal and interest, with a term of 36 months [7]. - Pianzaihuang's controlling shareholder plans to increase its stake in the company through a centralized bidding process, with a total investment of no less than 300 million yuan and no more than 500 million yuan [8]. - Zhongwei Semiconductor announced a price adjustment for MCU and Norflash products, with an increase of 15% to 50% due to rising costs and supply chain pressures [8][9]. - Yingxin Development plans to acquire 60% of Guangdong Changxing Semiconductor for 520 million yuan, which will enhance its revenue and profitability in the storage chip business [8].

| જેટ મેતિ | 公司 | 主要内容 | | --- | --- | --- | | 聚焦 | 臺韋点 | 筹划控制权变更事项 28日起停牌 | | | 万科A | 深铁集团向公司提供不超过23.6亿元借款 | | | 东材科技 | 实控人、副董事长熊海涛被留置 | | | 国泰海通等 | 业绩预增 | | | 多家券商 | | | | 康希诺 | 预计2025年净利润2450万元-2900万元 同比 扭亏为盈 | | | 何氏眼科 | 2025年度预盈2400万至3600万元 同比扭亏 | | | 常山北明 | 2025年度预盈3500万元 同比扭亏 | | | 国盾量子 | 预计2025年净利润500万元左右 同比扭亏为盈 | | | 宁波富邦 | 2025年净利润同比预增3099.59%-4379.43% | | | 金马游乐 | 2025年净利润同比预增811.17%-1069.56% | | | 怡球资源 | 2025年净利润同比预增620%-970% | | | 臻雷科技 | 2025年净利润同比预增530%-642% | | 业绩精选 | 英图川醋 | 2025年净利润同比预增428.3 ...

Core Viewpoint - The announcement from Jia Shitang indicates a potential change in its controlling shareholder and actual controller, leading to a temporary suspension of trading for up to two trading days starting January 28 [1][3]. Group 1: Company Overview - Jia Shitang is a major platform for China Everbright Group in the health sector, with its stock price at 16.40 CNY per share and a total market capitalization of 4.784 billion CNY as of January 27 [1][5]. - The major shareholders of Jia Shitang are China Everbright Medical Health Industry Co., Ltd. and China Everbright Industrial Group Co., Ltd., holding 14.36% and 14.12% of shares respectively [3][4]. Group 2: Financial Performance - Jia Shitang has experienced a continuous decline in performance, with net profits for the years 2022, 2023, and 2024 reported at 297 million CNY, 250 million CNY, and 161 million CNY respectively [8]. - The company's revenue for 2024 was approximately 24.02 billion CNY, a decrease of 19.93% from 2023, while net profit attributable to shareholders dropped by 35.75% to about 160.67 million CNY [10]. - For the first three quarters of 2025, the net profit attributable to shareholders decreased by 38.81% to 141 million CNY, with a significant drop in non-recurring profit as well [11].

Group 1 - The core point of the article is that Jiashitang's controlling shareholder and actual controller may change, leading to a suspension of trading starting January 28, with the suspension expected to last no more than two trading days [2][4][7] - Jiashitang is a major platform for China Everbright Group in the health sector, with a market capitalization of 4.784 billion yuan as of January 27, closing at 16.40 yuan per share, down 1.38% [2][3] - The potential change in control is due to China Everbright Industrial Group and its wholly-owned subsidiary, China Everbright Medical Health Industry Co., planning to transfer their shares in Jiashitang [4][7] Group 2 - As of the end of Q3 2025, China Everbright Medical and China Everbright Industrial are the largest shareholders of Jiashitang, holding 14.36% and 14.12% of shares, respectively [5] - Jiashitang's performance has been declining, with net profits for 2022, 2023, and 2024 reported at 297 million yuan, 250 million yuan, and 161 million yuan, respectively, indicating a downward trend [9] - The company's revenue for 2024 is reported at approximately 24 billion yuan, a decrease of 19.93% from 2023, with net profit dropping by 35.75% [13]

Group 1 - The core point of the news is that Jiashitang (002462) announced a potential change in its controlling shareholder and actual controller, leading to a suspension of trading starting January 28, with an expected duration of no more than two trading days [1][4] - Jiashitang is a major platform for China Everbright Group in the health sector, with a market capitalization of 4.784 billion yuan as of January 27, with its stock price at 16.40 yuan per share, down 1.38% [1][4] - The controlling shareholders, China Everbright Industrial Group and its subsidiary China Everbright Medical Health Industry, hold 14.36% and 14.12% of Jiashitang's shares, respectively [2][3] Group 2 - Jiashitang has experienced a continuous decline in performance, with net profits for the years 2022, 2023, and 2024 reported at 297 million yuan, 250 million yuan, and 161 million yuan, respectively [6] - The company's revenue for 2024 was reported at approximately 24 billion yuan, a decrease of 19.93% from 2023, while net profit attributable to shareholders dropped by 35.75% to approximately 161 million yuan [8] - For the first three quarters of 2025, Jiashitang's net profit decreased by 38.81% year-on-year to approximately 141 million yuan, primarily due to increased impairment losses and asset disposals [9]

嘉事堂（002462）(002462.SZ)发布公告，公司于2026年1月27日接到股东中国光大实业(集团)有限责任 公司(以下简称"光大实业")书面通知，光大实业及子公司中国光大医疗健康产业有限公司正在筹划公司 股权转让事宜，该事项可能导致公司控股股东、实际控制人发生变更。 经公司向深圳证券交易所申请，公司股票自2026年1月28日(星期三)开市起停牌，预计停牌时间不超过2 个交易日。 ...